

Zydus Healthcare SA (Pty) Ltd

(Registration number 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

**Financial statements
for the year ended 31 December 2024**

[Handwritten signature]

Zydus Healthcare SA (Pty) Ltd


(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

General Information

Country of incorporation and domicile	South Africa
Nature of business and principal activities	Pharmaceutical industry
Directors	IF Oliver A Dhaniraj T Msimanga
Registered office	22 Karee Street Southdowns office park Centurion, Gauteng South Africa 0157
Postal address	Postnet Suite 100 Private Bag X32 Highveld Park 0169
Bankers	Standard Chartered Bank ABSA Standard Bank
Auditors	GNR Auditors Chartered Accountants (SA) Registered Auditors
Company registration number	1998/014338/07
Tax reference number	9167004614
Preparer	The financial statements were internally compiled by: ADVA Auditors Incorporated



Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Index

The reports and statements set out below comprise the financial statements presented to the shareholder:

	Page
Directors' Responsibilities and Approval	3
Directors' Report	4 - 5
Independent Auditor's Report	6 - 7
Practitioner's Compilation Report	8
Statement of Financial Position	9
Statement of Comprehensive Income	10
Statement of Changes in Equity	11
Statement of Cash Flows	12
Accounting Policies	13 - 15
Notes to the Financial Statements	16 - 22
The following supplementary information does not form part of the financial statements and is unaudited:	
Detailed Income Statement	23 - 24

Level of assurance

These financial statements have been audited in compliance with the applicable requirements of the Companies Act of South Africa, 71 of 2008.



Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Directors' Responsibilities and Approval

The directors are required by the Companies Act of South Africa, 71 of 2008, to maintain adequate accounting records and are responsible for the content and integrity of the financial statements and related financial information included in this report. It is their responsibility to ensure that the financial statements fairly present the state of affairs of the company as at the end of the financial year and the results of its operations and cash flows for the period then ended, in conformity with the International Financial Reporting Standard for Small and Medium-sized Entities. The external auditors are engaged to express an independent opinion on the financial statements.

The financial statements are prepared in accordance with the International Financial Reporting Standard for Small and Medium-sized Entities and are based upon appropriate accounting policies consistently applied and supported by reasonable and prudent judgements and estimates.

The directors acknowledge that they are ultimately responsible for the system of internal financial control established by the company and place considerable importance on maintaining a strong control environment. To enable the directors to meet these responsibilities, the directors set standards for internal control aimed at reducing the risk of error or loss in a cost effective manner. The standards include the proper delegation of responsibilities within a clearly defined framework, effective accounting procedures and adequate segregation of duties to ensure an acceptable level of risk. These controls are monitored throughout the company and all employees are required to maintain the highest ethical standards in ensuring the company's business is conducted in a manner that in all reasonable circumstances is above reproach. The focus of risk management in the company is on identifying, assessing, managing and monitoring all known forms of risk across the company. While operating risk cannot be fully eliminated, the company endeavours to minimise it by ensuring that appropriate infrastructure, controls, systems and ethical behaviour are applied and managed within predetermined procedures and constraints.

The directors are of the opinion, based on the information and explanations given by management, that the system of internal control provides reasonable assurance that the financial records may be relied on for the preparation of the financial statements. However, any system of internal financial control can provide only reasonable, and not absolute, assurance against material misstatement or loss.

The directors have reviewed the company's cash flow forecast for the year to 31 December 2025 and, in the light of this review and the current financial position, they are satisfied that the company has or has access to adequate resources to continue in operational existence for the foreseeable future.

The external auditors are responsible for independently auditing and reporting on the company's financial statements. The financial statements have been examined by the company's external auditors and their report is presented on page 6 - 7.

The financial statements set out on pages 9 to 22, which have been prepared on the going concern basis, were approved by the board of directors on 16 May 2025 and were signed on its behalf by:

Approval of financial statements

IF Oliver

T Msimanga

A Dhamiraj

Friday, 16 May 2025

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Directors' Report

The directors have pleasure in submitting their report on the financial statements of Zydus Healthcare SA (Pty) Ltd for the year ended 31 December 2024.

1. Nature of business

Zydus Healthcare SA (Pty) Ltd was incorporated in South Africa with interests in the pharmaceutical industry. The company operates in South Africa.

There have been no material changes to the nature of the company's business from the prior year.

2. Review of financial results and activities

The financial statements have been prepared in accordance with International Financial Reporting Standard for Small and Medium-sized Entities and the requirements of the Companies Act of South Africa, 71 of 2008. The accounting policies have been applied consistently compared to the prior year.

Full details of the financial position, results of operations and cash flows of the company are set out in these financial statements.

GNR Auditors continued in office as auditors for the company for 2024.

3. Share capital

There have been no changes to the authorised or issued share capital during the year under review.

4. Directors

The directors in office at the date of this report are as follows:

Directors	Changes
IF Oliver	
N Y Shah	Resigned Thursday, 07 March 2024
A Dhaniraj	Appointed Thursday, 07 March 2024
T Msimanga	Appointed Thursday, 07 March 2024

5. Events after the reporting period

The directors are not aware of any material event which occurred after the reporting date and up to the date of this report.

6. Going concern

The directors believe that the company has adequate financial resources to continue in operation for the foreseeable future and accordingly the financial statements have been prepared on a going concern basis. The directors have satisfied themselves that the company is in a sound financial position and that it has access to sufficient borrowing facilities to meet its foreseeable cash requirements. The directors are not aware of any new material changes that may adversely impact the company. The directors are also not aware of any material non-compliance with statutory or regulatory requirements or of any pending changes to legislation which may affect the company.

7. Auditors

GNR Auditors will continue in office in accordance with section 90 of the Companies Act of South Africa, 71 of 2008.

8. Secretary

The company had no secretary during the year.

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Directors' Report

The financial statements set out on pages 9 to 22, which have been prepared on the going concern basis, were approved by the board of directors on 16 May 2025, and were signed on its behalf by:

Approval of financial statements



IF Oliver



T Msimanga



A Dhaniraj



Chartered Accountants (SA)
Registered Auditors

☎ 018 293 2726

☎ 018 462 8039 (Klerksdorp)

☎ 018 293 2753

☎ 018 462 8245 (Klerksdorp)

E-mail: admin@gnrauditors.co.za

E-mail: klerksdorp@gnrauditors.co.za

Peter Mokaba Avenue 86
Potchefstroom
2531

✉ 20395
Noordbrug
2522

Independent Auditor's Report

To the Shareholder of Zydus Healthcare SA (Pty) Ltd

Opinion

We have audited the financial statements of Zydus Healthcare SA (Pty) Ltd (the company) set out on pages 9 to 22, which comprise the statement of financial position as at 31 December 2024; and the statement of comprehensive income; the statement of changes in equity; and the statement of cash flows for the year then ended; and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the financial statements present fairly, in all material respects, the financial position of Zydus Healthcare SA (Pty) Ltd as at 31 December 2024, and its financial performance and cash flows for the year then ended, in accordance with International Financial Reporting Standard for Small and Medium-sized Entities and the requirements of the Companies Act of South Africa, 71 of 2008.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the company in accordance with the Independent Regulatory Board for Auditors' Code of Professional Conduct for Registered Auditors (IRBA Code) and other independence requirements applicable to performing audits of financial statements in South Africa. We have fulfilled our other ethical responsibilities in accordance with the IRBA Code and in accordance with other ethical requirements applicable to performing audits in South Africa. The IRBA Code is consistent with the corresponding sections of the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards). We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The directors are responsible for the other information. The other information comprises the information included in the document titled "Zydus Healthcare SA (Pty) Ltd financial statements for the year ended 31 December 2024", which includes the Directors' Report as required by the Companies Act of South Africa, 71 of 2008 and the supplementary information as set out on pages 23 to 24. The other information does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Statements

The directors are responsible for the preparation and fair presentation of the financial statements in accordance with the International Financial Reporting Standard for Small and Medium-sized Entities and the requirements of the Companies Act of South Africa, 71 of 2008, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

A Rademeyer, AL Nel, CR Rademeyer, M Rademeyer
PR903681

Independent Auditor's Report


Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with International Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with International Standards on Auditing, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:


- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



GMR Auditors
M Rademeyer
Partner
Chartered Accountants (SA)
Registered Auditors

16 May 2025





Practitioner's Compilation Report

To the Management of Zydus Healthcare SA (Pty) Ltd

We have compiled the financial statements of Zydus Healthcare SA (Pty) Ltd, as set out on pages 9 - 22, based on information you have provided. These financial statements comprise the statement of financial position of Zydus Healthcare SA (Pty) Ltd as at 31 December 2024, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and a summary of significant accounting policies and other explanatory information.

We performed this compilation engagement in accordance with International Standard on Related Services 4410 (Revised), Compilation Engagements.

We have applied our expertise in accounting and financial reporting to assist you in the preparation and presentation of these financial statements on the International Financial Reporting Standard for Small and Medium-sized Entities. We have complied with relevant ethical requirements, including principles of integrity, objectivity, professional competence and due care.

These financial statements and the accuracy and completeness of the information used to compile them are your responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the information you provided to us to compile these financial statements. Accordingly, we do not express an audit opinion or a review conclusion on whether these financial statements are prepared in accordance with the International Financial Reporting Standard for Small and Medium-sized Entities.

Corniel de Villiers
Chartered Accountant (SA)
Director
ADVA Auditors Inc
Registered Auditors

16 May 2025

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Statement of Financial Position as at 31 December 2024

Figures in Rand	Note(s)	2024	2023
Assets			
Non-Current Assets			
Property, plant and equipment	2	4 032 620	4 114 413
Investments in subsidiaries	3	63 997 517	63 997 517
Loans to group companies	4	90 117 511	90 117 511
Other assets	5	12 343 840	12 062 373
Deferred tax	6	1 445 880	1 710 585
		171 937 368	172 002 399
Current Assets			
Inventories	7	59 425 071	48 647 259
Trade and other receivables	8	284 821 447	182 395 978
Other assets	5	800 955	2 254 841
Current tax receivable		-	1 318 100
Cash and cash equivalents	9	27 790 361	19 582 421
		372 837 834	254 198 599
Total Assets		544 775 202	426 200 998
Equity and Liabilities			
Equity			
Share capital	10	140 504 149	140 504 149
Reserves		(33 217 210)	(33 217 210)
Retained income		51 206 243	38 126 321
		158 493 182	145 413 260
Liabilities			
Non-Current Liabilities			
Loans from group companies	4	58 728 332	61 193 097
Current Liabilities			
Trade and other payables	14	304 939 874	199 648 478
Other current liabilities	12	18 798 326	16 603 589
Current tax payable		514 333	-
Provisions	13	3 301 155	3 342 574
		327 553 688	219 594 641
Total Liabilities		386 282 020	280 787 738
Total Equity and Liabilities		544 775 202	426 200 998

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Statement of Comprehensive Income

Figures in Rand	Note(s)	2024	2023
Revenue	15	545 134 455	472 364 323
Cost of sales	16	(190 691 429)	(160 999 126)
Gross profit		354 443 026	311 365 197
Other income	17	187 789	202 775
Operating expenses		(336 944 765)	(302 771 302)
Operating profit		17 686 050	8 796 670
Interest revenue	19	50 526	408 699
Finance costs	20	217 750	(9 981 713)
Profit (loss) before taxation		17 954 326	(776 344)
Taxation	21	(4 874 404)	252 140
Profit (loss) for the year		13 079 922	(524 204)
Other comprehensive income		-	-
Total comprehensive income (loss) for the year		13 079 922	(524 204)



Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Statement of Changes in Equity

Figures in Rand	Share capital	Other NDR	Retained income	Total equity
Balance at 31 December 2022	140 504 149	(33 217 210)	38 650 525	145 937 464
Loss for the year	-	-	(524 204)	(524 204)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the year	-	-	(524 204)	(524 204)
Balance at 31 December 2023	140 504 149	(33 217 210)	38 126 321	145 413 260
Profit for the year	-	-	13 079 922	13 079 922
Other comprehensive income	-	-	-	-
Total comprehensive income for the year	-	-	13 079 922	13 079 922
Balance at 31 December 2024	140 504 149	(33 217 210)	51 206 243	158 493 182

Note(s)

11

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Statement of Cash Flows

Figures in Rand	Note(s)	2024	2023
Cash flows from operating activities			
Cash receipts from customers		442 811 775	434 415 989
Cash paid to suppliers and employees		(431 018 015)	(427 579 488)
Cash generated from operations	22	11 793 760	6 836 501
Tax paid	23	(2 777 266)	(2 104 821)
Net cash from operating activities		9 016 494	4 731 680
Cash flows from investing activities			
Purchase of property, plant and equipment	2	(771 944)	(4 218 030)
Proceeds from sale of property, plant and equipment	2	85 000	71 992
Interest Income		50 526	408 699
Net cash from investing activities		(636 418)	(3 737 339)
Cash flows from financing activities			
Finance costs		(172 136)	(126 312)
Total cash movement for the year		8 207 940	868 029
Cash and cash equivalents at the beginning of the year		19 582 421	18 714 392
Total cash at end of the year	9	27 790 361	19 582 421



Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Accounting Policies

1. Basis of preparation and summary of significant accounting policies

The financial statements have been prepared on a going concern basis in accordance with the International Financial Reporting Standard for Small and Medium-sized Entities, and the Companies Act of South Africa, 71 of 2008. The financial statements have been prepared on the historical cost basis, except for biological assets at fair value less point of sale costs, and incorporate the principal accounting policies set out below. They are presented in South African Rands.

These accounting policies are consistent with the previous period.

1.1 Property, plant and equipment

Property, plant and equipment are tangible assets which the company holds for its own use or for rental to others and which are expected to be used for more than one period.

Property, plant and equipment is initially measured at cost.

Cost includes costs incurred initially to acquire or construct an item of property, plant and equipment and costs incurred subsequently to add to, replace part of, or service it. If a replacement cost is recognised in the carrying amount of an item of property, plant and equipment, the carrying amount of the replaced part is derecognised.

Expenditure incurred subsequently for major services, additions to or replacements of parts of property, plant and equipment are capitalised if it is probable that future economic benefits associated with the expenditure will flow to the company and the cost can be measured reliably. Day to day servicing costs are included in profit or loss in the period in which they are incurred.

Property, plant and equipment is subsequently stated at cost less accumulated depreciation and any accumulated impairment losses, except for land which is stated at cost less any accumulated impairment losses.

Depreciation of an asset commences when the asset is available for use as intended by management. Depreciation is charged to write off the asset's carrying amount over its estimated useful life to its estimated residual value, using a method that best reflects the pattern in which the asset's economic benefits are consumed by the company.

The useful lives of items of property, plant and equipment have been assessed as follows:

Item	Depreciation method	Average useful life
Leasehold property	Straight line	Over period of the lease
Furniture and fixtures	Straight line	6 years
Motor vehicles	Straight line	5 years
Office equipment	Straight line	6 years
IT equipment	Straight line	3 years

When indicators are present that the useful lives and residual values of items of property, plant and equipment have changed since the most recent annual reporting date, they are reassessed. Any changes are accounted for prospectively as a change in accounting estimate.

Impairment tests are performed on property, plant and equipment when there is an indicator that they may be impaired. When the carrying amount of an item of property, plant and equipment is assessed to be higher than the estimated recoverable amount, an impairment loss is recognised immediately in profit or loss to bring the carrying amount in line with the recoverable amount.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected from its continued use or disposal. Any gain or loss arising from the derecognition of an item of property, plant and equipment, determined as the difference between the net disposal proceeds, if any, and the carrying amount of the item, is included in profit or loss when the item is derecognised.

1.2 Investments in subsidiaries

Investments in subsidiaries are measured at cost..



Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Accounting Policies

1.3 Financial instruments

Initial measurement

Financial instruments are initially measured at the transaction price (including transaction costs except in the initial measurement of financial assets and liabilities that are measured at fair value through profit or loss) unless the arrangement constitutes, in effect, a financing transaction in which case it is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial instruments at amortised cost

These include loans, trade receivables and trade payables. They are subsequently measured at amortised cost using the effective interest method. Debt instruments which are classified as current assets or current liabilities are measured at the undiscounted amount of the cash expected to be received or paid, unless the arrangement effectively constitutes a financing transaction.

At each reporting date, the carrying amounts of assets held in this category are reviewed to determine whether there is any objective evidence of impairment. If there is objective evidence, the recoverable amount is estimated and compared with the carrying amount. If the estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in profit or loss.

1.4 Tax

Current tax assets and liabilities

Current tax for current and prior periods is, to the extent unpaid, recognised as a liability. If the amount already paid in respect of current and prior periods exceeds the amount due for those periods, the excess is recognised as an asset.

The tax liability reflects the effect of the possible outcomes of a review by the tax authorities.

Deferred tax assets and liabilities

A deferred tax liability is recognised for all taxable temporary differences.

A deferred tax asset is recognised for all deductible temporary differences to the extent that it is probable that taxable profit will be available against which the deductible temporary difference can be utilised.

Deferred tax asset is recognised for the carry forward of unused tax losses to the extent that it is probable that future taxable profit will be available against which the unused tax losses can be utilised.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

Tax expenses

Tax expense is recognised in the same component of total comprehensive income or equity as the transaction or other event that resulted in the tax expense.

1.5 Inventories

Inventories are measured at the lower of cost and estimated selling price less costs to complete and sell, on the weighted average cost basis.

1.6 Impairment of assets

The company assesses at each reporting date whether there is any indication that any other asset may be impaired.

If there is any such indication, the recoverable amount of any affected asset (or group of related assets) is estimated and compared with its carrying amount. If the estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in profit or loss.

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Accounting Policies

1.6 Impairment of assets (continued)

If an impairment loss subsequently reverses, the carrying amount of the asset (or group of related assets) is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss been recognised for the asset (or group of assets) in prior years. A reversal of impairment is recognised immediately in profit or loss.

1.7 Share capital and equity

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities.

Ordinary shares are recognised at par value and classified as 'share capital' in equity. Any amounts received from the issue of shares in excess of par value is classified as 'share premium' in equity. Dividends are recognised as a liability in the year in which they are declared.

1.8 Provisions and contingencies

Provisions are recognised when the company has an obligation at the reporting date as a result of a past event; it is probable that the company will be required to transfer economic benefits in settlement; and the amount of the obligation can be estimated reliably.

Provisions are measured at the present value of the amount expected to be required to settle the obligation using a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the obligation. The increase in the provision due to the passage of time is recognised as interest expense.

Provisions are not recognised for future operating losses.

1.9 Revenue

Revenue is recognised to the extent that the company has transferred the significant risks and rewards of ownership of goods to the buyer, or has rendered services under an agreement provided the amount of revenue can be measured reliably and it is probable that economic benefits associated with the transaction will flow to the company. Revenue is measured at the fair value of the consideration received or receivable, excluding VAT.

Interest is recognised, in profit or loss, using the effective interest rate method.

1.10 Other liability

Zydus Healthcare SA (Pty) Ltd (Distributor) has entered into supply and distribution agreement with Zydus Lifesciences Limited (ultimate holding company)(Principal).

The agreement stipulates that the price of the products supplied to the distributor by the principal shall be readjusted on a quarterly basis to bring the EBITA of the distributor in line with the arm's length margin earned by comparable uncontrolled companies in the territory of the distributor.

The adjustment to be made in the form of overall price (True up) will be worked out mutually in order to maintain the EBITA outcome for the distributor to be within the range of comparable companies in a manner which satisfies the arm's length criteria under the transfer pricing regulations of both India and South Africa.



Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Notes to the Financial Statements

Figures in Rand

2024

2023

2. Property, plant and equipment

	2024			2023		
	Cost or revaluation	Accumulated depreciation and impairment	Carrying value	Cost or revaluation	Accumulated depreciation and impairment	Carrying value
Leasehold Improvements	2 192 855	(391 580)	1 801 275	2 582 032	(467 493)	2 114 539
Furniture and fixtures	1 814 984	(391 518)	1 423 466	1 754 834	(73 081)	1 681 753
Motor vehicles	-	-	-	319 161	(319 161)	-
Office equipment	200 802	(77 135)	123 667	344 410	(193 039)	151 371
IT equipment	1 242 890	(558 678)	684 212	511 296	(344 546)	166 750
Total	5 451 531	(1 418 911)	4 032 620	5 511 733	(1 397 320)	4 114 413

Reconciliation of property, plant and equipment - 2024

	Opening balance	Additions	Depreciation	Closing balance
Leasehold Improvements	2 114 539	-	(313 264)	1 801 275
Furniture and fixtures	1 681 753	40 350	(298 637)	1 423 466
Office equipment	151 371	-	(27 704)	123 667
IT equipment	166 750	731 594	(214 132)	684 212
	4 114 413	771 944	(853 737)	4 032 620

Reconciliation of property, plant and equipment - 2023

	Opening balance	Additions	Disposals	Depreciation	Closing balance
Leasehold Improvements	-	2 192 852	-	(78 313)	2 114 539
Furniture and fixtures	16 143	1 754 832	-	(89 222)	1 681 753
Office equipment	7 008	158 997	-	(14 634)	151 371
IT equipment	174 966	111 349	(7 019)	(112 546)	166 750
	198 117	4 218 030	(7 019)	(294 715)	4 114 413

3. Investments in subsidiaries

Name of subsidiary	% holding 2024	% holding 2023	Carrying amount 2024	Carrying amount 2023
Unlisted Investment - Alidac Pharmaceuticals SA (Pty) Ltd	100.00 %	100.00 %	63 697 517	63 697 517
Unlisted Investment - Script Management Services (Pty) Ltd	100.00 %	100.00 %	300 000	300 000
			63 997 517	63 997 517

4. Loans to (from) group companies

Alidac Pharmaceuticals SA (Pty) Ltd	90 117 511	90 117 511
No fixed terms of repayment exists at year end.		
Zydus International PVT Ltd	(58 728 332)	(61 193 097)
The loan has no fixed repayment terms and interest rates are linked to EURO LIBOR.		
	31 389 179	28 924 414

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Notes to the Financial Statements

Figures in Rand	2024	2023
4. Loans to (from) group companies (continued)		
Net loans to (from) group companies		
Non-current assets	90 117 511	90 117 511
Non-current liabilities	(58 728 332)	(61 193 097)
	31 389 179	28 924 414
5. Other assets		
Other non-current assets		
Deposits	805 159	828 692
Interest receivable	10 953 681	10 953 681
Loan - BEE Compliance	585 000	280 000
	12 343 840	12 062 373
Other current assets		
Customs VAT	503 385	-
VAT refund receivable	-	1 401 887
Prepaid expense	297 570	852 954
	800 955	2 254 841
Total other assets	13 144 795	14 317 214
6. Deferred tax		
The major components of the deferred tax balance are as follows:		
Reconciliation of deferred tax asset/(liability)		
At beginning of year	1 710 585	1 501 236
Recognised in profit or loss:		
Rate change adjustment - normal tax	-	(137 334)
Increases (decrease) in tax loss available for set off against future taxable income	(235 559)	235 559
Movement in temporary differences from inventory provision	(17 963)	(170 345)
Movement in temporary differences on salary related provisions	(11 183)	281 469
At end of year	1 445 880	1 710 585
7. Inventories		
Finished goods	61 404 027	50 692 744
	61 404 027	50 692 744
Inventories (write-downs)	(1 978 956)	(2 045 485)
	59 425 071	48 647 259
8. Trade and other receivables		
Trade receivables	284 028 179	181 378 767
Other receivables	793 268	1 017 211
	284 821 447	182 395 978

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Notes to the Financial Statements

Figures in Rand	2024	2023
9. Cash and cash equivalents		
Cash and cash equivalents consist of:		
Bank balances	27 790 361	19 582 421
10. Share capital		
Authorised number of shares		
Ordinary shares	70 000 000	70 000 000
Preference shares	10 000 000	10 000 000
	80 000 000	80 000 000
Issued number of shares		
Ordinary shares	57 704 149	57 704 149
Preference shares	5 877 000	5 877 000
	63 581 149	63 581 149
Issued		
Ordinary	57 704 149	57 704 149
Preference	82 800 000	82 800 000
	140 504 149	140 504 149
11. FCTR Reserve		
Reported as at 31 December	(33 217 210)	(33 217 210)
12. Other current liabilities		
VAT Control	1 321 794	-
Interest payable	17 391 514	15 316 635
Other	85 018	149 655
Customs VAT	-	1 137 299
	18 798 326	16 603 589

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Notes to the Financial Statements

Figures in Rand

2024

2023

13. Provisions

Reconciliation of provisions - 2024

	Opening balance	Created/(reversed) during the year	Closing balance
Provision for leave pay	134 796	-	134 796
Provision for annual bonus and incentives	3 207 778	(41 419)	3 166 359
	3 342 574	(41 419)	3 301 155

Reconciliation of provisions - 2023

	Opening balance	Created/(reversed) during the year	Closing balance
Provision for leave pay	508 641	(373 845)	134 796
Provision for annual bonus and incentives	2 300 098	907 680	3 207 778
	2 808 739	533 835	3 342 574

14. Trade and other payables

Trade payables	217 410 900	120 582 808
Other payables	87 528 974	79 065 670
	304 939 874	199 648 478

15. Revenue

Sale of goods	443 055 626	382 136 963
Out-Licensing	90 628 045	80 168 590
Tender Sales	11 271 167	9 926 691
Other	179 617	132 079
	545 134 455	472 364 323

16. Cost of sales

Sale of goods

Cost of goods sold	190 691 429	160 999 126
--------------------	-------------	-------------

17. Other Income

Profit on sale of assets	85 000	64 973
SETA Refund	102 789	137 802
	187 789	202 775

18. Auditor's remuneration

Fees	498 000	454 100
Consulting	13 300	12 300
	511 300	466 400

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Notes to the Financial Statements

Figures in Rand	2024	2023
19. Investment revenue		
Interest revenue		
Interest Income	11 333	408 699
SARS interest received	39 193	-
	50 526	408 699
20. Finance costs		
Bank charges	127 738	105 165
ERF (gain)/loss	(3 116 900)	7 341 887
Interest expense	2 727 014	2 513 514
Bank interest	44 398	21 147
	(217 750)	9 981 713
21. Taxation		
Major components of the tax expense (Income)		
Current taxation		
South African normal tax - year	4 609 699	-
South African normal tax - prior period (over) under provision	-	(42 791)
	4 609 699	(42 791)
Deferred taxation		
South African deferred tax - current year	264 705	(209 349)
	4 874 404	(252 140)
22. Cash generated from operations		
Net profit (loss) before taxation	17 954 326	(776 344)
Adjustments for:		
Depreciation, amortisation, impairments and reversals of impairments	853 737	294 716
Profit on sale of assets	(85 000)	(64 973)
Movement in loans to or from group companies	(2 464 765)	6 055 409
Finance cost: Non-cash	(389 886)	9 855 401
Finance cost	172 136	126 312
Interest received	(50 526)	(408 699)
Changes in working capital:		
(Increase) decrease in inventories	(10 777 812)	836 259
(Increase) decrease in trade and other receivables	(102 425 469)	(60 953 836)
Movement in other current- and non-current assets	1 172 419	1 144 405
Movement in other current- and non-current liabilities	2 584 623	(5 242 411)
Increase (decrease) in trade and other payables	105 291 396	55 436 427
Movement in provisions	(41 419)	533 835
	11 793 760	6 836 501
23. Tax paid		
Balance at beginning of the year	1 318 100	(829 512)
Current tax for the year recognised in profit or loss	(4 609 699)	42 791
Balance at end of the year	514 333	(1 318 100)
	(2 777 266)	(2 104 821)

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Notes to the Financial Statements

Figures in Rand

2024

2023

24. Related parties

Relationships

Ultimate holding company

Holding company

Zydus Lifesciences Limited

Zydus Worldwide DMCC

Subsidiaries

Alidac Pharmaceuticals SA (Pty) Ltd (formerly known as Simayla Pharmaceuticals (Pty) Ltd
Script Management Services (Pty) Ltd
Zydus International Pvt. Ltd.

Other group companies

Related party balances and transactions with entities over which the company has control, joint control or significant influence

Related party balances

Loan accounts - Owing (to) by related parties

Alidac Pharmaceuticals SA (Pty) Ltd

Zydus International PVT Ltd

90 117 511
(58 728 332)

90 117 511
(61 193 097)

Amounts included in Trade receivable (Trade Payable) regarding related parties

Zydus Lifesciences Limited

Zydus Lifesciences Limited - Regulatory cost

Script Management Services (Pty) Ltd

(280 784 666)
22 179 877
(4 066 729)

(118 738 413)
13 313 735
(1 503 513)

True up adjustment (payable)/ receivable

Zydus Lifesciences Limited

Zydus Lifesciences Limited - true up Receivable

64 263 727
74 365 434

(5 895 251)
43 964 408

Amounts included in Interest Receivable (Interest Payable) regarding related parties

Alidac Pharmaceuticals SA (Pty) Ltd

Zydus International PVT Ltd

10 953 681
(17 391 514)

10 953 681
(15 316 635)

Investments in subsidiaries

Script Management Services (Pty) Ltd

Alidac Pharmaceuticals SA (Pty) Ltd

300 000
63 697 517

300 000
63 697 517

Share capital

Zydus Worldwide DMCC

(140 504 149)

(140 504 149)

Related party transactions

Interest paid to (received from) related parties

Zydus International PVT Ltd

2 727 014

2 513 514

Purchases from (sales to) related parties

Zydus Lifesciences Limited

150 481 154

129 933 230

Administration fees paid to (received from) related parties

Script Management Services (Pty) Ltd

71 500

54 100

Data fee expense to related parties

Script Management Services (Pty) Ltd

124 816 720

125 535 832

True up expense (Income)

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Notes to the Financial Statements

Figures in Rand	2024	2023
24. Related parties (continued)		
Zydus Lifesciences Limited	(2 560 805)	(15 339 974)
Directors' remuneration		
T Msimanga	1 201 414	-
A Dhaniraj	3 385 480	-
V Shiva	-	749 299
NY Shah	-	731 795
RS Sundarraj	-	2 155 830



Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Detailed Income Statement

Figures in Rand	Note(s)	2024	2023
Revenue			
Sale of goods		443 055 626	382 136 963
Other		179 617	132 079
Out-Licensing		90 628 045	80 168 590
Tender Sales		11 271 167	9 926 691
	15	545 134 455	472 364 323
Cost of sales			
Opening stock		(48 647 259)	(49 483 518)
Purchases		(203 448 197)	(160 162 867)
Closing stock		61 404 027	48 647 259
	16	(190 691 429)	(160 999 126)
Gross profit		354 443 026	311 365 197
Other income			
SETA Refund		102 789	137 802
Profit on disposal of fixed assets		85 000	64 973
		187 789	202 775
Operating expenses			
Administration and management fees		(74 000)	(54 100)
Auditors remuneration	18	(511 300)	(466 400)
Consulting and professional fees		(48 382)	(79 739)
Consulting fees - BEE		(3 263 732)	(3 836 566)
Delivery expenses		(48 681 020)	(41 202 205)
Depreciation, amortisation and impairments		(853 737)	(294 716)
Distribution fees		(13 126 594)	(12 417 448)
Employee Benefits		(36 800)	(336 560)
Employee Cost - Stipend/ Learner		(1 307 515)	(460 028)
Employee costs		(54 074 073)	(47 711 514)
HR Admin Fees		(1 053 110)	(903 636)
IT expenses		(2 836 072)	(2 398 259)
Insurance		(744 156)	(980 422)
Lease rentals on operating lease		(2 320 627)	(1 797 817)
Loss on exchange differences		(2 845 937)	(1 249 245)
Market research : Other expenses		(147 642 430)	(137 383 981)
Market research: IMS Data Fees		(1 095 126)	(2 761 714)
Marketing expenses : CRM		(772 426)	(455 569)
Marketing expenses : Product Information		(2 495 712)	(4 163 565)
Marketing expenses : Sales promotion		(5 324 386)	(3 156 600)
Marketing expenses : Seminar & Conferences		(1 099 139)	(1 418 537)
Marketing expenses : Sponsorships		(3 677 426)	(3 447 071)
Other expenses		(3 758 948)	(5 496 174)
Regulatory and lab testing		(3 847 736)	(3 947 412)
Repairs and maintenance		(248 609)	(166 415)
Sales Incentives		(9 682 583)	(9 562 026)
Staff welfare		(312 927)	(420 710)
Subscriptions		(61 108)	(163 409)
Sundry balances written off		(2 725 972)	-
Telephone and fax		(1 100 683)	(1 010 698)
Travel - local		(21 322 499)	(15 028 766)
		(336 944 765)	(302 771 302)

Zydus Healthcare SA (Pty) Ltd

(Registration number: 1998/014338/07)

Trading as Zydus Healthcare SA (Pty) Ltd

Financial Statements for the year ended 31 December 2024

Detailed Income Statement

Figures in Rand	Note(s)	2024	2023
Operating profit		17 686 050	8 796 670
Interest income	19	50 526	408 699
Finance costs	20	217 750	(9 981 713)
		268 276	(9 573 014)
Profit (loss) before taxation		17 954 326	(776 344)
Taxation	21	(4 874 404)	252 140
Profit (loss) for the year		13 079 922	(524 204)

